NCT06357988 2025-10-20Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)National Cancer Institute (NCI)Phase 2 Active not recruiting35 enrolled